FLIGHT1 and FLIGHT2: Efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 192, Issue 9, 2015, Pages 1068-1079

  Mahler, Donald A ^a,b   Kerwin, Edward ^c   Ayers, Tim ^d   Taylor, Angel Fowler ^d   Maitra, Samopriyo ^e   Thach, Chau ^d   Lloyd, Mark ^d   Patalano, Francesco ^d   Banerji, Donald ^d  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Valley Regional Hospital   (United States)

^c Clinical Research Institute of Southern Oregon   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Novartis Healthcare Pvt Ltd   (India)

Author keywords

COPD; Long acting 2 agonists; long acting muscarinic antagonist; clinical trial; fixed dose combination

Indexed keywords

GLYCOPYRRONIUM BROMIDE; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; INDACATEROL; PLACEBO; BRONCHODILATING AGENT; INDAN DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINOLONE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BACTERIAL INFECTION; BRONCHITIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPERTENSION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; OROPHARYNX PAIN; PARALLEL DESIGN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLYCOPYRROLATE; HUMANS; INDANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84946575010     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201505-1048OC     Document Type: Article

References (38)

1. National Vital Statistics Report: Deaths: final data for 2012 [accessed 2015 Apr 5]. Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr63/nvsr63-09.pdf
2. National Institutes of Health. COPD: the more you know, the better for you and your loved ones. Bethesda, MD: National Heart, Lung, and Blood Institute; 2013 [accessed 2015 Mar 3]. Available from: https://www.nhlbi.nih.gov/files/docs/public/lung/copd-atrisk.pdf
3. National Institutes of Health. Morbidity & mortality: 2012 chart book on cardiovascular, lung, and blood diseases. Bethesda, MD: National Heart, Lung, and Blood Institute; 2012 [accessed 2015 May 3]. Available from: https://www.nhlbi.nih.gov/files/docs/research/2012-ChartBook-508.pdf
4. Hasegawa K, Tsugawa Y, Tsai CL, Brown DF, Camargo CA Jr. Frequent utilization of the emergency department for acute exacerbation of chronic obstructive pulmonary disease. Respir Res 2014;15:40.
5. Blasi F, Cesana G, Conti S, Chiodini V, Aliberti S, Fornari C, Mantovani LG. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One 2014;9:e101228.
6. Miravitlles M, Sicras A, Crespo C, Cuesta M, Brosa M, Galera J, Lahoz R, Lleonart M, Riera MI. Costs of chronic obstructive pulmonary disease in relation to compliance with guidelines: a study in the primary care setting. Ther Adv Respir Dis 2013;7:139-150.
7. Rutten-van Mölken MP, Goossens LM. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics 2012;30:271-302.
8. American Lung Association. State of lung disease in diverse communities 2010; 2010 [accessed 2013 Dec 5]. Available from: http://ala1-old.pub30.convio.net/assets/documents/publications/lung-disease-data/solddc-2010.pdf
9. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2015 [accessed 2015 May 3]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD-Report-2015.pdf
10. Cazzola M, Molimard M. The scientific rationale for combining longacting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010;23:257-267.
11. Tashkin DP, Donohue JF, Mahler DA, Huang H, Goodwin E, Schaefer K, Hanrahan JP, Andrews WT. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 2009;103:516-524.
12. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005;26:214-222.
13. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Zaagsma J, Mueller A, Cornelissen PJ. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med 2010;104: 995-1004.
14. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129:509-517.
15. Vogelmeier C, Kardos P, Harari S, Gans SJ, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008;102: 1511-1520.
16. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2011 [accessed 2015 May 3]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD2011-Summary.pdf
17. Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Stat Med 2009;28: 586-604.
18. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-mg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011;37: 273-279.
19. Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M, Kramer B; INTIME study investigators (INdacaterol & TIotropium: Measuring Efficacy). Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respir Res 2010;11:135.
20. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013;107:1538-1546.
21. van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 2010;65:1086-1091.
22. Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, Banerji D. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42: 1484-1494.
23. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1: 199-209.
24. Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patientreported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res 2011;12:40.
25. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014;189:250-255.
26. Donohue JF. Minimal clinically important differences in COPD lung function. COPD 2005;2:111-124.
27. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002;19: 398-404.
28. Mahler DA, Witek TJ Jr. The MCID of the transition dyspnea index is a total score of one unit. COPD 2005;2:99-103.
29. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327.
30. Rossi A, Khirani S, Cazzola M. Long-acting beta2-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety. Int J Chron Obstruct Pulmon Dis 2008;3:521-529.
31. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and metaanalysis. JAMA 2008;300:1439-1450.
32. Wedzicha JA, Dahl R, Buhl R, Schubert-Tennigkeit A, Chen H, D'Andrea P, Fogel R, Banerji D. Pooled safety analysis of the fixeddose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 2014;108:1498-1507.
33. Van de Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. COPD 2010;7:418-427.
34. Franssen FM, Rochester CL. Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter? Eur Respir Rev 2014;23:131-141.
35. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005;128:2099-2107.
36. Liesker JJ, Postma DS, Beukema RJ, ten Hacken NH, van der Molen T, Riemersma RA, van Zomeren EH, Kerstjens HA. Cognitive performance in patients with COPD. Respir Med 2004; 98:351-356.
37. Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ 2011;14: 486-496.
38. Yu AP, Guérin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SI, Setyawan J. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med 2011;105: 1861-1871.